Opzelura 1.5 %

Ruxolitinib, the active ingredient in Opzelura 1.5%, is a Janus kinase (JAK) inhibitor presented as a 1.5% cream for topical use. It is used for the treatment of mild to moderate atopic dermatitis and nonsegmental vitiligo in specified patient groups. GNH USA supplies Opzelura 1.5% as a licensed, GDP-compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Opzelura 1.5% is a prescription medication that works by inhibiting specific enzymes involved in the immune response, thereby reducing inflammation and improving skin conditions. It is the first topical JAK inhibitor approved in the United States for its indicated uses.

Opzelura 1.5% is a topical medication used to manage specific skin conditions by modulating the immune response.

- Atopic dermatitis (eczema): Reduces inflammation, itching, and rash severity in mild to moderate cases when other topical treatments are ineffective or inadvisable. - Nonsegmental vitiligo: Promotes repigmentation of the skin by targeting immune pathways involved in pigment loss. - Short-term and non-continuous treatment: Used for flare-ups or worsening symptoms, typically for a few weeks until symptoms improve.

Opzelura 1.5% may cause various side effects, ranging from common to serious.

Common Side Effects: - Skin reactions: Acne, itching, and redness at the application site. - Upper respiratory infections: Common cold symptoms such as nasopharyngitis. - Headache: Mild to moderate headaches. - Urinary tract infection: Symptoms may include pain or burning during urination. - Fever: Mild to moderate increase in body temperature.

Serious or Rare Side Effects: - Serious infections: Increased risk of infections, including tuberculosis and shingles. - Cancer: Potential risk of certain cancers, including lymphoma and skin cancers. - Immune system problems: May increase susceptibility to infections due to immune suppression. - Allergic reactions: Severe allergic reactions, though rare, can occur.

Opzelura 1.5% should be used with caution and under medical supervision.

- Infection risk: Avoid use during active infections or in immunocompromised individuals. - Skin application: Do not apply to eyes, mouth, or vagina; use only on affected skin areas. - Body surface area: Limit use to no more than 20% of the body surface area. - Sun exposure: Limit sun exposure and use protective clothing and sunscreen. - Monitoring: Regularly check for signs of infection or skin changes. - Storage: Store at room temperature: keep in the original pack, protect from moisture.

Opzelura 1.5% may interact with other medications, requiring careful monitoring.

Major Interactions (Avoid): - Therapeutic biologics: Avoid concurrent use to prevent excessive immune suppression. - Other JAK inhibitors: Avoid to prevent additive immune suppression. - Strong immunosuppressants: Avoid to prevent severe immune system compromise.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs: Monitor for increased risk of infections or other immune-related side effects. - Medications affecting the immune system: Monitor for signs of immune suppression or other adverse effects. - Medications metabolized by CYP3A4: Monitor for potential changes in drug metabolism.